TickerFacts.

Company research / RNLXY

Renalytix plc (RNLXY)

Also trades as RENXF. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

CIK 0001811115 · OTC · Services-Medical Laboratories

  • Sector Services
  • Fiscal year ends Jun 30

Not updated since 2024-06-30. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

For the year ended 2024-06-30, Renalytix plc reported revenue of $2.29M. Revenue fell 32.7% from the prior annual period.

Key ratios (year ended 2024-06-30)

6.8%
Gross margin
n/m
Operating margin
n/m
Net margin
-32.7%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2025-01-16

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-30
Revenue$2.29M$3.40M$2.97M$1.49M$0n/an/a
Cost of Revenue$2.13M$2.68M$2.10M$858.0K$0n/an/a
Gross Profit$156.0K$720.0K$874.0K$633.0K$0n/an/a
R&D Expense$9.29M$14.30M$14.65M$10.04M$4.57M$4.32Mn/a
Operating Income-$29.61M-$42.22M-$53.18M-$31.92M-$10.31M-$42.34Mn/a
Depreciation & Amortization$364.0K$508.0K$489.0K$282.0K$70.0K$31.0Kn/a
EBITDA-$29.24M-$41.71M-$52.69M-$31.63M-$10.24M-$42.31Mn/a
Net Income-$33.46M-$45.61M-$45.28M-$35.34M-$9.84M-$42.30Mn/a
EPS (Diluted)-$0.31-$0.55-$0.67-$0.49-$0.17n/an/a
Total Assets$7.97M$30.63M$50.06M$78.58M$20.88M$9.70M$115.0K
Total Liabilities$15.83M$23.66M$19.46M$7.12M$4.97M$1.15M$617.0K
Shareholders' Equity-$7.85M$6.97M$30.61M$71.46M$15.91M$8.55M-$502.0K
Cash & Equivalents$4.68M$24.68M$41.33M$65.13M$13.29M$8.20M$82.0K
Operating Cash Flow-$30.11M-$34.09M-$45.92M-$28.40M-$9.52M-$6.16Mn/a
Capital Expendituresn/a$0$557.0K$773.0K$804.0K$309.0Kn/a
Free Cash Flown/a-$34.09M-$46.48M-$29.17M-$10.33M-$6.46Mn/a
Shares Outstanding154.37M93.78M74.76M72.20M59.42M53.82M20.00M
Weighted Average Diluted Shares108.18M82.21M73.84M71.48M59.08Mn/an/a
EPS (Basic)-$0.31-$0.55-$0.62-$0.49-$0.17n/an/a